| Current Price | $29.30 | Mkt Cap | $2.9B |
|---|---|---|---|
| Open | $29.16 | P/E Ratio | 51.87 |
| Prev. Close | $28.97 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $28.52 - $29.30 | Volume | 73,891 |
| 52-Wk Range | $19.51 - $64.00 | Avg. Daily Vol. | 1,826,462 |
A development stage nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy.
| Current Price | $29.30 | Mkt Cap | $2.9B |
|---|---|---|---|
| Open | $29.16 | P/E Ratio | 51.87 |
| Prev. Close | $28.97 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $28.52 - $29.30 | Volume | 73,891 |
| 52-Wk Range | $19.51 - $64.00 | Avg. Daily Vol. | 1,826,462 |
The best Bull and Bear pitches based on recency and number of recommendations.
Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade,MarketWatch•September 6, 2018MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday,… More
“Arrow - Heading” downward.Arrowhead Research Corporation (Arrowhead) is a development stage nanotechnology company, commercializing technologies in the areas of life sciences, electronics and energy. Arrowhead operates four majority-owned… More
Read the most recent pitches from players about ARWR.
Recs
Bigsef77
(65.03)
Submitted: 9/6/2018 11:23:29 AM :
Start Price:
$1.52
NASDAQ:ARWR Score:
+1,797.24
Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade
,MarketWatch•September 6, 2018
MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday, after upbeat results of the company's treatment for chronic hepatitis B prompted an upgrade at B.
Recs
Quickcard
(< 20)
Submitted: 10/10/2017 5:07:56 PM :
Start Price:
$4.02
NASDAQ:ARWR Score:
+618.69
Pharma companies with what are doing research with verifiable positive results in treatment for especially intractable medical conditions seem to be on a roll. I don't see this should not continue, especially as DNA/RNA research is reaching new highs at the same time.
Recs
motto1628
(54.91)
Submitted: 10/4/2015 2:59:52 AM :
Start Price:
$5.99
NASDAQ:ARWR Score:
+351.56
Functional cure for Hep B
Find the members with the highest scoring picks in ARWR.
trackchardan (< 20) Score: +2,548.57
The Score Leader is the player with the highest score across all their picks in ARWR.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
|
mistermiranga | 99.78 | 12/1/2016 |
|
5Y | $1.41 | +1,961.92% | +17.90% | +1,944.02 | 0 Comment |
| Bigsef77 | 65.03 |
|
|
3Y | $1.52 | +1,806.05% | +8.81% | +1,797.24 | 1 Comment | |
| KidJones | 37.01 | 4/22/2013 |
|
5Y | $1.78 | +1,527.53% | +66.57% | +1,460.96 | 0 Comment | |
| whoodatstockhot | 84.32 | 7/8/2013 |
|
5Y | $2.02 | +1,334.16% | +58.35% | +1,275.80 | 0 Comment | |
| EvilEmpire | 30.24 | 2/28/2013 |
|
5Y | $2.20 | +1,216.82% | +70.82% | +1,146.00 | 0 Comment | |
| MFBurritoSquat | 86.82 | 12/19/2012 |
|
3M | $2.23 | +1,199.10% | +78.30% | +1,120.80 | 0 Comment | |
| hayrettin | 70.86 | 8/24/2017 |
|
5Y | $2.50 | +1,061.12% | +6.11% | +1,055.01 | 0 Comment | |
| beecha | < 20 | 9/19/2017 |
|
5Y | $3.35 | +764.78% | +3.79% | +760.98 | 0 Comment | |
| AJL7 | < 20 | 2/3/2016 |
|
5Y | $3.26 | +788.65% | +35.56% | +753.09 | 0 Comment | |
|
|
Under5 | < 20 | 9/13/2017 |
|
5Y | $3.42 | +748.32% | +3.80% | +744.51 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
